The Trade

ETON at $22.32. $600M market cap. Three analysts. The market is pricing guided FY2026 numbers at ≈18x forward EBITDA and treating this as a small specialty pharma company. It's not. It's a rare disease compounder hitting the inflection point where operating leverage turns a portfolio of niche products into a margin machine.

The market is wrong about three things: the size of the DESMODA addressable market (adult CDI, 3x the pediatric population, disclosed for the first time on this call), the speed of margin inflection (14 points of gross margin expansion in one year), and the option value in five concurrent clinical programs.

Probability-weighted 12-month EV: $27.04, +21% from current. Asymmetric: Breakout scenario (+115%) is 1.7x the magnitude of Disappointment (-69%), and twice as probable (25% vs 12%).

Scale-in buy. Stock has run 25% in a month. RSI 77.5. You're paying up. The edge is in knowing what the market hasn't modeled.

The Mechanism

ETON does one thing. It takes generic molecules that have been around for decades — desmopressin (1970s), hydrocortisone (1950s), propranolol (1960s) — and reformulates them as oral liquids for children who can't swallow tablets. Files via FDA's 505(b)(2) pathway, which references the generic's safety data. Gets orphan drug designation because each disease has fewer than 5,000 pediatric patients. Distributes exclusively through two specialty pharmacies with zero patient copay.

The result: $80,000/year for DESMODA. Generic desmopressin tablets cost $240/year. That's a 250x premium. ALKINDI SPRINKLE, the first product using this model, charges 100-350x over generic hydrocortisone and has been growing for 5 years. Nobody has challenged it.

Why does it work? Three structural reasons. First, the populations are tiny — 400 pediatric dermatologists prescribe Hemangiol, a few hundred pediatric endocrinologists prescribe DESMODA. No single insurer has enough patients to justify the fight. Second, formulation patents (DESMODA's extends to 2044) plus orphan exclusivity (7 years) mean there is no generic substitution path. Third, patients pay nothing — the zero-copay program shifts all price sensitivity to payers, who write the check because the total system cost is rounding error for CMS.

Here's what makes it compound. ETON has 18 sales reps. That's the entire commercial organization. Those 18 people call on pediatric endocrinologists, pediatric dermatologists, and Wilson disease specialists. Every time ETON acquires a new product targeting one of those same prescriber pools, the marginal cost of adding it is close to zero. ALKINDI and DESMODA go through the same 300 pediatric endocrinologists. Hemangiol adds 400 pediatric dermatologists with 7 employees from Pierre Fabre. Same specialty pharmacies. Same patient assistance program. Same infrastructure.

That's why EBITDA margins go from 8% (FY2024) to 20% (FY2025) to 30%+ (FY2026 guided) to 50% (2028 target). Not because prices go up, but because every incremental product shares the same fixed cost base. At 10 products, the infrastructure is diluted. At 13-14 products — the target — it's pure operating leverage.

What Changed

Three findings from the Q4 2025 earnings call (March 19, 2026):

1. DESMODA's Addressable Market Just Tripled

DESMODA was approved for central diabetes insipidus with a label that says "all ages." ETON's own $30-50M peak sales forecast was based on the pediatric market only — 3,000-4,000 children. The adult CDI population is 9,000-10,000 patients.

CEO Brynjelsen: "Our historic market assessment and $30 million to $50 million peak sales forecast were based solely on the pediatric market. However, we believe there could be a meaningful incremental opportunity within the adult population."

Within two weeks of launch, ETON added 3,000 adult endocrinologist prescriber targets and started a 90-day pilot. The CCO confirmed 97-98% of existing pediatric endo relationships are already DESMODA targets. This is a real commercial effort with existing infrastructure, not a press release aspiration.

The pediatric case is airtight — kids can't swallow tablets. The adult case is weaker clinically but larger commercially. Even 5% adult penetration at $80K = $38M/year incremental, nearly doubling the pediatric peak.

The analyst spread confirms the market hasn't converged: HC Wainwright targets $52 (pricing adult upside), B. Riley targets $31 (not pricing it), Craig-Hallum $35. When three analysts can't agree within a 67% range, there's information still being processed.

Cross-corpus validation: 5,735 earnings call transcripts searched. Zero mentions of desmopressin, CDI, or DDAVP outside ETON's own call. Nobody else is even looking at this market.

2. Margin Inflection Is a Fact, Not a Forecast

Q4 2025 adjusted gross margin: 73%. Q4 2024: 59%. Fourteen points in one year. First GAAP profitable quarter in company history — $1.5M net income.

The FY2025 headline gross margin of 53.5% was a distortion. A $5.1M non-cash inventory step-up charge from the INCRELEX acquisition flowed through COGS. Strip it out: normalized margin was ≈59.7%, in line with prior year. The step-up is substantially burned through. It won't recur.

Both DESMODA and Hemangiol are expected to have margins "well above" company average. Mix shift is favorable from here. Management guided FY2026 adjusted gross margin "comfortably above 70%," ramping to 75-80%.

3. Hemangiol: A Monopoly for 1.2x Revenue

$14M cash for exclusive US rights to Hemangiol — the only FDA-approved treatment for infantile hemangioma. No dilution. No new debt. The product did ≈$12M under Pierre Fabre's stewardship through traditional wholesaler distribution with $55/month copays.

ETON's plan: specialty pharmacy conversion, zero copay, rare disease reps, May 1 relaunch. This is the exact playbook that worked on GALZIN, INCRELEX, and ALKINDI. The prescriber universe — ≈400 pediatric dermatologists — is the kind of hyper-concentrated base ETON's model is built for.

Pierre Fabre isn't distressed (EUR 3.2B revenue, actively acquiring rare disease assets). This is a EUR 3.2B company shedding a $12M product that's subscale for its infrastructure. ETON picks it up and it's immediately additive.

The Cascade

ETON's thesis is a cascade: pricing power → gross margins → operating leverage → OCF → debt paydown → M&A capacity → next product → repeat.

The most fragile link is DESMODA pricing + cash position. Post-Hemangiol, ETON has ≈$12M in cash. SWK principal payments start May 2026 ($9M across 2026). At guided OCF (>$33M adj. EBITDA), the math works and the cascade accelerates — debt gets paid, balance sheet cleans up, another acquisition becomes possible. CEO confirmed "at least one more product acquisition before 2027."

If DESMODA scripts disappoint or Hemangiol integration stumbles, OCF misses, and the cascade stalls. The cushion between "everything works" and "we need to raise capital" is one bad quarter.

Factor Decomposition

Quantitative regression (250 days): 91% idiosyncratic variance. SPY explains 4.1% (beta 0.40), healthcare 2.7%, momentum 2.4%. This stock moves on its own fundamentals. The +57% 1-year return is alpha, not beta.

Three factors carry the thesis:

1. DESMODA launch (30-35% of value). Strong edge — we know pricing, adult market expansion, and the zero-competitor landscape before the market has modeled it.

2. Rare disease pricing power (cross-cutting, affects all products). Moderate edge. This is the structural bet. If 505(b)(2) orphan pricing persists, every product compounds at 80%+ gross margins. If it erodes — PBM formulary changes, drug pricing legislation, a Congressional hearing that puts "$80,000 for a reformulated generic" in a headline — every product is impaired simultaneously. Latent factor. Not currently priced because it hasn't materialized.

3. Pipeline optionality (20-25% collective). Low edge on individual outcomes, but the calendar is dense: ET-700 PET study (April 2026, >$100M peak if positive), KHINDIVI under-5 NDA supplement (Q3 2026, ">$20M/quarter" incremental), INCRELEX label harmonization (5x US market if successful). We know what and when, not whether.

Edge-weighted variance: ≈75% in factors where we have informational advantage. Passes threshold.

The Bear Case

The bull case is a machine. The bear case is that the machine runs on a fuel nobody has stress-tested.

The 250x Premium Has Never Been Tested in Adults

Every ETON product to date has targeted pediatric patients. The clinical argument — "these children cannot swallow tablets and need precise liquid dosing" — has been unchallenged for 5 years. That argument dissolves the moment you apply it to adults who can swallow tablets just fine.

DESMODA's adult CDI market is the first time ETON has attempted to charge orphan-level pricing for a population that has an obvious generic alternative. If a single large PBM — Express Scripts, CVS Caremark, OptumRx — decides to require step therapy through generic desmopressin tablets before authorizing DESMODA for adults, the adult market is functionally zero. And that PBM decision could be made by one person on a formulary committee who reads the same "$80,000 vs $240" comparison in this memo.

The 90-day adult pilot that started in March is the binary signal. If adult endocrinologists report payer resistance by June-July, the Breakout scenario collapses. The adult market goes from $38M/year incremental to zero, and DESMODA reverts to a pediatric-only product — still good, but not the thesis.

Wilson Disease Is Waking Up After 40 Years

ETON management didn't mention Monopar Therapeutics on the call. That omission matters.

Monopar (MNPR, $400M market cap) has ALXN1840, a once-daily oral copper chelator that completed Phase 3 — 214 patients, met primary endpoint, 3x greater copper mobilization versus standard-of-care. NDA filing planned H1 2026. If approved, it would be the first novel Wilson disease treatment since penicillamine in the 1980s.

The current treatment paradigm is chelation first, then zinc maintenance (GALZIN). ALXN1840 doesn't directly compete with zinc — it's a chelator, different stage of therapy. But if ALXN1840 demonstrates sustained efficacy as monotherapy, the zinc maintenance step becomes optional. GALZIN's 300 patients keep refilling, but new patient starts slow. ET-700's >$100M peak, which assumes zinc remains standard-of-care for maintenance, shrinks to $30-50M.

GALZIN near-term is safe. ET-700 long-term is not.

The Balance Sheet Is Running Hot

$12M cash. $9M SWK debt due 2026. $21M due 2027. Interest at SOFR+6.75%. Incremental FDA program fees of $2.8M (ETON exceeded the $50M orphan exemption threshold). Five concurrent clinical studies costing incremental R&D.

This is a company that just spent $14M on an acquisition while carrying $30M in high-cost debt and guiding $110M in revenue. The math works — barely — if OCF is positive and growing. If DESMODA launch is slower than the CEO's "six months to peak" timeline and Hemangiol takes two quarters to transition distribution, you have a quarter where OCF is negative and the SWK payment is due. Management has no revolver, no credit facility, no backup plan disclosed in the 10-K.

Scenarios

EV: $27.04 (+21%). Edge contribution: $2.64/share. Of that, $1.44 comes from the adult CDI probability shift (55% of total edge). The adult market IS the trade.

Conviction

The question this memo comes down to: is ETON Recordati at year 3 of a 30-year compounding journey, or is it the next specialty pharma roll-up to blow up when someone notices the markup?

Recordati built a EUR 834M rare disease business at 37% EBITDA margins through serial acquisitions of orphan products. ETON is running the same playbook at 1/15th the scale. The CEO has hit every public goal he's set — 10 products (done), $100M revenue run-rate (done). He just set four new ones ($200M by Q4 2027, 50% EBITDA by 2028, $500M by 2030, largest US rare disease portfolio) and attached his credibility: "We generally set goals which are achievable."

The pricing risk is real. But orphan drug pricing has survived every challenge thrown at it for decades. Patient populations under 5,000 are simply too small for systemic reform to target. The total cost to the healthcare system — a few hundred million across all of ETON's products — is noise. And every year that ALKINDI keeps growing at 100-350x generic premiums without pushback, the model's Lindy effect strengthens.

I'm buying at $22. Sizing at ≈4% of GMV. Scale-in: starter now, add on pullback to $19-20 or post-earnings confirmation on May 12. Stop below $15. The stock is overbought and I'm paying for some of the move. But the alternative — waiting for the pullback that may not come while DESMODA scripts ramp and Hemangiol relaunches May 1 — is worse. The edge is perishable.

Catalyst calendar: Hemangiol relaunch May 1. Earnings May 12 (first DESMODA revenue disclosure — >$5M in partial quarter validates pricing). ET-700 PET readout H2 2026. KHINDIVI NDA Q3 2026. Four shots in six months to shift the probability distribution toward Breakout.

Sized for survival, positioned for compounding.

Evidence